13/05/2024 – AB Science today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib Download PDF Post navigationPreviousPrevious post:A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientsNextNext post:Annual financial results as of 31 December, 2023Related PostsAB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseOctober 28, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024Revenues for the first half of 2024 and update on AB Science’s activitiesOctober 10, 2024AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million eurosOctober 9, 2024AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024AB Science announces the success of a 5.0 million euros capital increaseSeptember 30, 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseOctober 28, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024
AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million eurosOctober 9, 2024
AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024
